drugset / Trial / NCT00199056

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

NCT00199056

Phase 4 Completed 225 enrolled Goethe University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy. Thereafter patients receive individualised treatment stratified according to relapse risk with stem cell transplantation for patients with high and very high risk of relapse. Patients with standard risk receive further consolidation and reinduction chemotherapy. In parallel minimal residual disease (MRD) is evaluated. A MRD based risk stratification and treatment decision is developed.

Timeline

Start
1999-10
Primary completion
2003-11
Completion
2005-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified
Subject Cytarabine Small molecule
Subject Daunorubicin Small molecule
Subject Dexamethasone Small molecule
Subject Doxorubicin Other / unclassified
Subject Etoposide Small molecule
Subject Fludarabine Small molecule
Subject Idarubicin Small molecule
Subject Ifosfamide Small molecule
Subject MERCAPTOPURINE ANHYDROUS Small molecule
Subject Methotrexate Small molecule
Subject Prednisolone Other / unclassified
Subject Teniposide Small molecule
Subject Thioguanine Small molecule
Subject Vincristine Small molecule
Subject Vindesine Small molecule
Subject asparaginase Protein / enzyme biologic